Alerts will be sent to your verified email
Verify EmailLINCOLN
Lincoln Pharma
|
Ind-Swift
|
Bliss GVS Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
R&D as a % of Total Sales
|
3.1 % | n/a | 2.57 % |
Financials
|
|||
5 yr Average ROE
|
16.41 % | 30.85 % | 7.87 % |
5yr average Equity Multiplier
|
1.35 | -1.62 | 1.33 |
5yr Average Asset Turnover Ratio
|
0.87 | 0.48 | 0.63 |
5yr Avg Net Profit Margin
|
14.05 % | -45.85 % | 9.44 % |
Price to Book
|
2.2 | 0.0 | 1.29 |
P/E
|
14.0 | 8.34 | 15.29 |
5yr Avg Cash Conversion Cycle
|
10.4 Days | -212.7 Days | 169.17 Days |
Inventory Days
|
41.92 Days | 74.98 Days | 51.37 Days |
Days Receivable
|
86.41 Days | 85.13 Days | 187.07 Days |
Days Payable
|
100.81 Days | 267.01 Days | 75.42 Days |
5yr Average Interest Coverage Ratio
|
44.62 | -6.47 | 15.0 |
5yr Avg ROCE
|
20.85 % | -66.14 % | 14.67 % |
5yr Avg Operating Profit Margin
|
21.16 % | -5.79 % | 21.43 % |
5 yr average Debt to Equity
|
0.03 | -2.08 | 0.13 |
5yr CAGR Net Profit
|
8.4 % | n/a | -4.95 % |
5yr Average Return on Assets
|
12.15 % | -16.74 % | 5.91 % |
Shareholdings
|
|||
Promoter Holding
|
49.78 % | 55.58 % | 34.9 % |
Share Pledged by Promoters
|
0.0 | 42.81 % | 0.0 |
Change in Promoter Holding (3 Yrs)
|
12.0 % | 0.03 % | 1.66 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | -0.04 % |
Lincoln Pharma
|
Ind-Swift
|
Bliss GVS Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|